119 related articles for article (PubMed ID: 35872546)
1. Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment of pancreatic cancer.
Zheng X; Li X; Tian L; Wu B; Yu J; Wang C; Sun X; Ma X; Chen L; Li Y
Eur J Med Chem; 2022 Nov; 241():114607. PubMed ID: 35872546
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
Li R; Gong L; Sun J; Liang Z; He J; Huang J; Ning X; Song H; Li R; Zhang Q; Lin Z; Yin Y
Bioorg Chem; 2024 Mar; 144():107134. PubMed ID: 38237389
[TBL] [Abstract][Full Text] [Related]
3. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
Liu H; Wu B; Ge Y; Huang J; Song S; Wang C; Yao J; Liu K; Li Y; Li Y; Ma X
Bioorg Med Chem; 2017 Dec; 25(24):6313-6321. PubMed ID: 29102081
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity.
Qu M; Liu Z; Zhao D; Wang C; Zhang J; Tang Z; Liu K; Shu X; Yuan H; Ma X
Bioorg Med Chem; 2017 Aug; 25(15):3989-3996. PubMed ID: 28576633
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
Su Y; Li R; Ning X; Lin Z; Zhao X; Zhou J; Liu J; Jin Y; Yin Y
Eur J Med Chem; 2019 Sep; 177():32-46. PubMed ID: 31129452
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
Wang S; Zhang RH; Zhang H; Wang YC; Yang D; Zhao YL; Yan GY; Xu GB; Guan HY; Zhou YH; Cui DB; Liu T; Li YJ; Liao SG; Zhou M
Eur J Med Chem; 2021 Oct; 222():113573. PubMed ID: 34091209
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma.
Wu B; Yang S; Deng T; Wang C; Jin Y; Yu J; Xu Y; Chen L; Li Y; Ma X
Bioorg Chem; 2021 Nov; 116():105330. PubMed ID: 34547646
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel FAK inhibitors with better selectivity over IR than TAE226.
Chen T; Liu Y; Liu J; Tang M; Huang H; Bai C; Si W; Yang T; Yuan X; Wen Y; Chen L
Bioorg Chem; 2022 Jul; 124():105790. PubMed ID: 35452915
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor.
Fang Y; Wang D; Xu X; Liu J; Wu A; Li X; Xue Q; Wang H; Wang H; Zhang H
Eur J Med Chem; 2017 Feb; 127():493-508. PubMed ID: 28109944
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
Tan H; Liu Y; Gong C; Zhang J; Huang J; Zhang Q
Eur J Med Chem; 2021 Nov; 223():113670. PubMed ID: 34214842
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
Pathania D; Kuang Y; Sechi M; Neamati N
Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
Chen T; Liu Y; Shi M; Tang M; Si W; Yuan X; Wen Y; Chen L
Bioorg Med Chem Lett; 2021 Dec; 54():128433. PubMed ID: 34757216
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel 2,4-Dianilinopyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and
Han C; Shen K; Wang S; Wang Z; Su F; Wu X; Hu X; Li M; Han J; Wu L
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299462
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines.
Ai M; Wang C; Tang Z; Liu K; Sun X; Ma T; Li Y; Ma X; Li L; Chen L
Bioorg Chem; 2020 Jan; 94():103408. PubMed ID: 31706682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]